top of page


Current Clinical Trials
Clinical Study (Sanofi EFC16461 - Dupilumab for Chronic Idiopathic Urticaria)

The company Sanofi is currently recruiting chronic idiopathic urticaria patients for a clinical study of its new drug Dupixent in multiple sites in Canada and the US. Dupixent is already approved for use in asthma, eczema and nasal polyps.

If you are interested in participating, you should discuss this option with your doctor. More information on study sites and admissibility criteria is available at      

bottom of page